Assisted Reproductive Technology (ART) Market Size By Type (Product {Media, Catheters, Needles, Vitrification Devices, Incubators}, Procedure {Fresh Donor, Fresh Nondonor, Frozen Donor, Frozen Nondonor, Embryo/Egg Banking}, Procedure Technology {In-Vitro Fertilization (IVF) [IVF with Intracytoplasmic Sperm Injection (ICSI), IVF without ICSI], Artificial Insemination-Intrauterine Insemination (AI-IUI), Frozen Embryo Replacement (FER)]}), By End-User/Provider (Hospitals, Fertility Clinics), Regional Outlook, Industry Analysis Report, Growth Potential, Competitive Market Share & Forecast, 2023 – 2032

Industry Statistics

Assisted Reproductive Technology Market was valued at more than USD 35 billion in 2022 and is poised to grow significantly at over 6.5% CAGR from 2023 to 2032 driven by the rising prevalence of infertility worldwide.
 

Several factors, such as hereditary problems, delayed childbirth, and changing lifestyles, which include the adoption of sedentary eating habits, excessive smoking, and alcohol use, are contributing to the high infertility rate. Additionally, sexually transmitted infections, post-partum infections, post-abortion infections, and medically iatrogenic infections are increasing the prevalence of infertility among the population base, thereby increasing the demand for assisted reproductive procedures and products. According to National Center for Biotechnology Information (NCBI), infertility affects around 20% of couples globally, with figures in the European Union reaching as high as 25%.
 

Get more details on this report - Request Free Sample PDF
 

Furthermore, prominent R&D efforts to advance assisted reproductive technology, along with the presence of significant industry players that continuously invest in the development of innovative products with enhanced features and effectiveness, are projected to augment market expansion. In addition, the development of healthcare facilities as well as rising government initiatives to educate people about the benefits of ART is foreseen to enhance the overall business scenario between 2023 and 2032.
 

High treatment costs may limit assisted reproductive technology market progress

The high cost of ART treatment as compared to conventional procedures in developed and certain emerging nations is adversely impacting product adoption. These procedures are not covered by insurance or reimbursement plans, which is also impeding the assisted reproductive technology business growth. However, government initiatives to promote ART technology and technical improvements may help overcome this barrier.
 

High success rates of ART procedures to promote segment expansion

Get more details on this report - Request Free Sample PDF
 

As per type, the industry is classified into product and procedure. The report cites that the assisted reproductive technology market share from the procedure segment accounted for more than USD 33 billion in revenue in 2022 and is estimated to witness substantial growth from 2023 to 2032. Soaring live birth rates facilitated by fresh non-donors are anticipated to bolster the need for ART procedures. Notably, research suggests that over 2.5 million cycles are performed globally in a year. Thus, the high adoption of in-vitro fertilization technology and IVF procedures is likely to fuel segment expansion.
 

Advancements in assisted reproductive technology to favor fertility clinics segment

Get more details on this report - Request Free Sample PDF
 

The fertility clinics end-user/provider segment held over 54% share in the assisted reproductive technology market in 2022 and is projected to expand notably through 2032. Advancements in assisted reproductive technologies, coupled with the growing integration of AI and robotic technologies, are raising the demand for infertility treatments. Additionally, favorable government initiatives are expected to stimulate segment progress.
 

Increasing adoption of fertility procedures to augment North America industry share

Get more details on this report - Request Free Sample PDF
 

According to the report, the North America assisted reproductive technology market is estimated to reach a valuation of over USD 19.5 billion by 2032. This is attributed to the increasing infertility rate, coupled with the growing acceptance of fertility procedures, such as IVF and ART, among patients across the region. As per research, infertility affects around 11% of women and 9% of males of reproductive age in the U.S. Moreover, technological advancements and rising disposable income are expected to boost the uptake of fertility services in North America, which is likely to be profitable for the regional business.
 

Strategic acquisitions to define the competitive landscape

Some prominent companies operating in the assisted reproductive technology market are LABORATOIRE CCD, Cooper Companies, Gynotec, Nidacon International AB, Vitrolife AB, Fertility Clinic Tokyo, Olympus Corporation, Hamilton Thorne, KITAZATO, SevenHills Hospital, and Tambre Fertility Clinic Madrid, among others. These firms generally engage in efficient strategies, including partnerships, acquisitions, and product portfolio expansions, with the aim to increase their business share.
 

COVID-19 impact on assisted reproductive technology market trends

The COVID-19 pandemic negatively impacted the assisted reproductive technology industry owing to mobility restrictions, coupled with safety concerns during treatments. The declining number of ART treatments after the COVID-19 outbreak hampered product demand in fertility clinics. Several groups have launched measures to maintain reproductive health standards. In addition, collaborative initiatives by several firms to generate product demand are likely to present growth opportunities in the coming years.
 

The assisted reproductive technology market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

By Type

• Product
  • Media
  • Catheters
  • Needles
  • Vitrification Devices
  • Incubators
  • Others
• Procedure
  • Fresh Donor
  • Fresh Nondonor
  • Frozen Donor
  • Frozen Nondonor
  • Embryo/Egg Banking
  • By procedure technology
  • In-vitro fertilization (IVF)
    • IVF with Intracytoplasmic Sperm Injection (ICSI)
    • IVF without ICSI
  • Artificial Insemination - Intrauterine Insemination (AI-IUI)
  • Frozen Embryo Replacement (FER)
  • Others

By Service Provider

• Hospitals
• Fertility clinics
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Others
• Asia Pacific
  • China
  • India
  • Japan
  • Others
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Others
• Middle East and Africa
  • South Africa
  • Egypt
  • Others